Bruton Tyrosine Kinase (BTK) Gene Mutation Analysis
X-linked agammaglobulinemia (XLA) is an inherited immunodeficiency disorder characterized by the absence of mature B cells, resulting in severe antibody deficiency and recurrent infections. The disease is caused by mutations in the Bruton Tyrosine Kinase (BTK) gene that is present on the long arm of the X-chromosome. The gene encodes for a cytoplasmic tyrosine kinase belonging to the Tec family of nonreceptor protein-tyrosine kinases that act as signal transduction molecules. These proteins contain five regions; PH, TH, SH3, SH2 and kinase domains. Mutations causing XLA may affect any of these domains. More than 400 mutations have been associated with the disease most common being missense mutations.
BTK plays a role in the maturation of Pro-B-Cells to Pre-B-cells. Thus, there is a failure of B cell development in affected individuals. Immunoglobulin-secreting plasma cells are deficient or absent, resulting in immunoglobulin deficiency (hypogammaglobulinemia) or absence (agammaglobulinemia). Deficiency of immunoglobulins results in increased risk of bacterial infections. Clinically XLA presents with early onset and recurrent bacterial infections, as well as apparent absence of lymph nodes and tonsils.
The vast majority of XLA patients are diagnosed in childhood (median age of diagnosis in patients with sporadic XLA is 26 months), although some patients are recognized in early adulthood or later in life. The diagnosis of XLA in both children and adults indicates that the disorder demonstrates considerable clinical phenotypic heterogeneity, depending on the position of the mutations within the gene.
Females are typically carriers and asymptomatic. Testing in adult females should be limited to those in their child-bearing years. The preferred approach for confirming a diagnosis of XLA in males and identifying carrier females is to initially test for Btk protein expression on B cells by flow cytometry and follow up with genetic testing for BTK mutations. However, normal results by flow cytometry do not rule out the presence of a BTK mutations that result in normal protein expression but aberrant protein function.
- As an aid in diagnosis of X-linked agammaglobulinemia
- Carrier screening in female with family history
Mutations detected in women confirms their carrier status. If a mutation is detected in a man, it confirms the diagnosis. Mutations are reported with mutation status or phenotype followed by clinical interpretation.
Example
Mutation detected
This individual was shown to have one copy (heterozygous) of the following familial mutation in the BTK gene: missense substitution - g.100500969, c.862C>T, p.Arg288Trp (p.R288W).
This female individual has a heterozygous missense variation in Exon 10 of the BTK gene, which encodes the SH2 domain of the Btk protein. This variation results in a change from a basic amino acid (Arg) to an aromatic, hydrophobic amino acid (Trp) at position 288 in the Btk protein. In male patients, this variant is reported to be possibly pathogenic.
Negative for mutation analyzed (Mutation not detected)
Whole blood (EDTA). Buccal swab and saliva can be also used.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Medicine (Baltimore). 1996 Nov;75(6):287-99. [PMID: 8982147]
- Front Biosci. 2000 Dec 1;5:D917-28. [PMID: 11102316]
- Front Biosci. 1997 Jan 1;2:d27-42. [PMID: 9159207]
- Curr Top Microbiol Immunol. 2016;393:67-105. [PMID: 26341110]
- J Leukoc Biol. 1999 Mar;65(3):286-90. [PMID: 10080529]
- Dev Immunol. 2001;8(3-4):171-81. [PMID: 11785667]